ZOLADEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zoladex, and when can generic versions of Zoladex launch?
Zoladex is a drug marketed by Tersera and is included in two NDAs.
The generic ingredient in ZOLADEX is goserelin acetate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the goserelin acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZOLADEX?
- What are the global sales for ZOLADEX?
- What is Average Wholesale Price for ZOLADEX?
Summary for ZOLADEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 45 |
| Clinical Trials: | 154 |
| Drug Prices: | Drug price information for ZOLADEX |
| What excipients (inactive ingredients) are in ZOLADEX? | ZOLADEX excipients list |
| DailyMed Link: | ZOLADEX at DailyMed |
Recent Clinical Trials for ZOLADEX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Panbela Therapeutics | Phase 2 |
| Prostate Cancer Foundation | Phase 2 |
| Novartis Pharmaceuticals | Phase 1 |
Pharmacology for ZOLADEX
| Drug Class | Gonadotropin Releasing Hormone Receptor Agonist |
| Mechanism of Action | Gonadotropin Releasing Hormone Receptor Agonists |
US Patents and Regulatory Information for ZOLADEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 019726-001 | Dec 29, 1989 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 020578-001 | Jan 11, 1996 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZOLADEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 019726-001 | Dec 29, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 019726-001 | Dec 29, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 019726-001 | Dec 29, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 020578-001 | Jan 11, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 020578-001 | Jan 11, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Tersera | ZOLADEX | goserelin acetate | IMPLANT;IMPLANTATION | 020578-001 | Jan 11, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZOLADEX
See the table below for patents covering ZOLADEX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Czechoslovakia | 199674 | METHOD OF PRODUCING POLYPEPTIDES | ⤷ Sign Up |
| Sweden | 437837 | POLYPEPTID FOR ATT KONTROLLERA OCH/ELLER FORBETTRA REPRODUKTIONEN HOS DJUR JEMTE VETERINER KOMPOSITION INNEHALLANDE NEMNDA POLYPEPTID SOM AKTIV BESTANDSDEL | ⤷ Sign Up |
| Canada | 2398066 | PROTECTION DE SURETE A FONCTIONNEMENT AUTOMATIQUE POUR SERINGUE (AUTOMATICALLY OPERABLE SAFETY SHIELD SYSTEM FOR SYRINGES) | ⤷ Sign Up |
| German Democratic Republic | 136738 | VERFAHREN ZUR HERSTELLUNG NEUER POLYPEPTIDE | ⤷ Sign Up |
| Austria | A328384 | ⤷ Sign Up | |
| Denmark | 164845 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
